Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aura Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Aura Biosciences, Inc.

AURA

Aura Biosciences, Inc.

About Aura Biosciences, Inc.

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing precision oncology therapies focused on solid tumors to preserve organ function. Its lead product candidate, belzupacap sarotalocan (bel-sar), is a virus-like drug conjugate designed for targeted, light-activated tumor cell killing and immune activation. Aura targets ocular and urologic cancers, including choroidal melanoma and bladder cancer, aiming to offer vision- and organ-sparing treatments with potential long-term antitumor immunity.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Aura Biosciences, Inc.

1
1
Aura Biosciences, Inc. Aura Biosciences Reports $33.7 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Aura Biosciences, Inc. Aura Biosciences Reports $106.2 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Aura Biosciences, Inc. Aura Biosciences Reports $26.1 Million Net Loss in Q3 2025, Increases R&D Spending

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aura Biosciences, Inc. Aura Biosciences Reports $27M Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aura Biosciences, Inc. Aura Biosciences Reports $27.5 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aura Biosciences, Inc. Aura Biosciences Reports $86.9 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Aura Biosciences, Inc. Aura Biosciences Reports Financial Results, Advances Lead Candidate Bel-Sar in Phase 3 Trial

Via official filing (AI summary) | over 1 year ago | 0 comments